Skip to Content

American Funds New Perspective 529E CNPEX

Medalist Rating as of | See American Funds Investment Hub
  • NAV / 1-Day Return 56.15  /  +0.88 %
  • Total Assets 128.1 Bil
  • Adj. Expense Ratio
  • Expense Ratio 1.020%
  • Distribution Fee Level Low
  • Share Class Type Level Load
  • Category Global Large-Stock Growth
  • Investment Style Large Growth
  • Min. Initial Investment 250
  • Status Open
  • TTM Yield
  • Turnover 17%

USD | NAV as of Apr 22, 2024 | 1-Day Return as of Apr 22, 2024, 10:14 PM GMT+0

Morningstar’s Analysis CNPEX

Will CNPEX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A Manager Retirement and Addition on American Funds New Perspective Does Not Change Our View

null Stephen Welch

Stephen Welch

Analyst Note

American Funds’ parent Capital Group announced that veteran manager Jonathan Knowles will step off American Funds New Perspective on Jan. 2, 2024, and retire from the firm on April 1, 2024. Knowles has spent 18 of his 31 years at Capital Group managing this strategy. In November, Anne-Marie Peterson and Kohei Higashi will officially join the management team, bringing the total number of named managers to 11. While Knowles’ retirement is a loss, it is one that Capital Group is equipped to handle. These changes do not alter the strategy’s High People rating or its Morningstar Medalist Ratings.

Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings CNPEX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 22.4
Top 10 Holdings
% Portfolio Weight
Market Value USD

Capital Group Central Cash Fund

4.48 6.1 Bil
Cash and Equivalents

Microsoft Corp

3.79 5.2 Bil

Meta Platforms Inc Class A

3.35 4.6 Bil
Communication Services

Novo Nordisk A/S Class B

2.74 3.7 Bil

Broadcom Inc

2.35 3.2 Bil

Taiwan Semiconductor Manufacturing Co Ltd

2.28 3.1 Bil

Fujitsu Ltd

2.15 2.9 Bil

Tesla Inc

1.58 2.1 Bil
Consumer Cyclical

Eli Lilly and Co

1.51 2.1 Bil

AstraZeneca PLC

1.42 1.9 Bil